A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2019
Price : $35 *
At a glance
- Drugs Trientine (Primary) ; Vemurafenib
- Indications Malignant melanoma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 17 Nov 2015 Status changed from active, no longer recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 11 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.